Haesuk Park
Haesuk Park
Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy
Email verificata su cop.ufl.edu - Home page
Titolo
Citata da
Citata da
Anno
Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden
Z Younossi, H Park, L Henry, A Adeyemi, M Stepanova
Gastroenterology 150 (7), 1599-1608, 2016
2742016
Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
ZM Younossi, H Park, S Saab, A Ahmed, D Dieterich, SC Gordon
Alimentary pharmacology & therapeutics 41 (6), 544-563, 2015
1312015
Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis
H Park, C Park, Y Kim, KL Rascati
Annals of Pharmacotherapy 46 (11), 1453-1469, 2012
1232012
A meta‐analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection
H Park, A Adeyemi, L Henry, M Stepanova, Z Younossi
Journal of viral hepatitis 22 (11), 897-905, 2015
842015
Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection
S Saab, SC Gordon, H Park, M Sulkowski, A Ahmed, Z Younossi
Alimentary pharmacology & therapeutics 40 (6), 657-675, 2014
792014
Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C
ZM Younossi, H Park, SC Gordon, JR Ferguson, A Ahmed, D Dieterich, ...
Am J Manag Care 22 (6), SP205-11, 2016
562016
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism …
GK Dawwas, J Brown, E Dietrich, H Park
The Lancet Haematology 6 (1), e20-e28, 2019
432019
Evaluation of health care costs and utilization patterns for patients with gout
H Park, KL Rascati, K Prasla, T McBayne
Clinical therapeutics 34 (3), 640-652, 2012
432012
Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD
H Park, C Chen, W Wang, L Henry, RL Cook, DR Nelson
Hepatology 67 (2), 492-504, 2018
402018
Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase
H Park, KL Rascati, KA Lawson, JC Barner, KM Richards, DC Malone
Journal of Managed Care Pharmacy 20 (8), 862-876, 2014
372014
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: the quality-adjusted cost of care
ZM Younossi, H Park, D Dieterich, S Saab, A Ahmed, SC Gordon
Medicine 95 (41), 2016
322016
Cardiovascular outcomes of sodium glucose cotransporter‐2 inhibitors in patients with type 2 diabetes
GK Dawwas, SM Smith, H Park
Diabetes, Obesity and Metabolism 21 (1), 28-36, 2019
312019
The value of cure associated with treating treatment‐naïve chronic hepatitis C genotype 1: Are the new all‐oral regimens good value to society?
ZM Younossi, H Park, D Dieterich, S Saab, A Ahmed, SC Gordon
Liver International 37 (5), 662-668, 2017
242017
Direct medical costs and utilization of health care services to treat pneumonia in the United States: an analysis of the 2007–2011 Medical Expenditure Panel Survey
H Park, AO Adeyemi, KL Rascati
Clinical therapeutics 37 (7), 1466-1476. e1, 2015
232015
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective
H Park, KL Rascati, MS Keith, P Hodgkins, M Smyth, D Goldsmith, ...
Value in Health 14 (8), 1002-1009, 2011
232011
Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States
H Park, W Wang, L Henry, DR Nelson
Hepatology 69 (3), 1032-1045, 2019
212019
Cost-effectiveness of expanded newborn screening in Texas
SK Tiwana, KL Rascati, H Park
Value in Health 15 (5), 613-621, 2012
212012
Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity‐matched cohort study
H Park, GK Dawwas, X Liu, MH Nguyen
Journal of Internal Medicine 286 (6), 711-722, 2019
182019
Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
GK Dawwas, SM Smith, H Park
Cardiovascular diabetology 17 (1), 102, 2018
132018
Scales of smoking-related self-efficacy, beliefs, and intention: assessing measurement invariance among intermittent and daily high school smokers
KL Sterling, KH Ford, H Park, AL McAlister
American Journal of Health Promotion 28 (5), 310-315, 2014
122014
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20